The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 13, 2021
Filed:
Jun. 13, 2017
Glaxosmithkline Intellectual Property Development Limited, Middlesex, GB;
Cancer Research Technology Ltd., London, GB;
Nicholas David Adams, Collegeville, PA (US);
Andrew B. Benowitz, Collegeville, PA (US);
María Lourdes Rueda Benede, Collegeville, PA (US);
Karen Anderson Evans, Collegeville, PA (US);
David T Fosbenner, Collegeville, PA (US);
Bryan Wayne King, Collegeville, PA (US);
Mei Li, Collegeville, PA (US);
Juan Ignacio Luengo, Collegeville, PA (US);
William Henry Miller, Collegeville, PA (US);
Alexander Joseph Reif, Collegeville, PA (US);
Stuart Paul Romeril, Collegeville, PA (US);
Stanley J. Schmidt, Collegeville, PA (US);
Roger J. Butlin, Manchester, GB;
Kristin M. Goldberg, Manchester, GB;
Allan M. Jordan, Manchester, GB;
Christopher S. Kershaw, Manchester, GB;
Ali Raoof, Manchester, GB;
Bohdan Waszkowycz, Manchester, GB;
GlaxoSmithKline Intellectual Property Development Limited, Middlesex, GB;
Cancer Research Technology Ltd., London, GB;
Abstract
The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Y, X, X, R, R, R, Rand Rare as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.